

THE STOCK EXCHANGE OF HONG KONG LIMITED

(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

REGULATORY FORMS

FORMS RELATING TO LISTING

FORM G

GEM

COMPANY INFORMATION SHEET

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this information sheet, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

Company name:

Huakang Biomedical Holdings Company Limited 華康生物醫學控股有限公司

Stock code (ordinary 8622 shares):

This information sheet contains certain particulars concerning the above company (the "Company") which is listed on GEM of The Stock Exchange of Hong Kong Limited (the "Exchange"). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules"). They will be displayed at the Exchange's website on the internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of 21 March 2024

A. General

	Dego 1 of 5	December 2022
(please distinguish the status of the directors - Executive, Non-Executive or Independent Non-Executive)	Chow Ching Man (周靖文)	
	Chan Kin Sang (陳健生)	
	Cheng Faat Ting Gary (鄭發丁)	
	Chow Kwok Fai Joseph (周國輝)	
	Independent non-executive Directors	
	He Jiaming (何嘉明)	
	Poon Lai Yin Michael (潘禮賢)	
	Zhang Chunguang (張春光)	
	Zhang Shuguang (張曙光)	
Names of directors:	Executive Directors	
Name of Sponsor(s):	RHB Capital Hong Kong Limited	
Date of initial listing on GEM:	13 December 2018	
Place of incorporation:	Cayman Islands	

THE STOCK EXCHANGE OF HONG KONG LIMITED (A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

Name(s) of substantial shareholder(s): (as such term is defined in rule 1.01 of the GEM Listing Rules) and their respective interests in the ordinary shares and other securities of the Company	Name of Shareholder Crystal Grant Limited ("Crystal Grant") (Notes 1)	Number of Shares 138,672,000	Percentage of Shareholding 29.54%
	Zhang Shuguang ("Mr. Zhang") (Notes 1 and 3)	142,672,000	30.39%
	Kokusai Resources Company Limited ("Kokusai") <i>(Notes 2)</i>	72,752,000	15.50%
	Lau Lai Yee (Notes 2)	72,752,000	15.50%
	Notes:		······
	1. Crystal Grant is beneficially of Zhang is deemed to be intere Grant for the purpose of the (Chapter 571 of the Laws of I	sted in all the Sha e Securities and I	res held by Crystal Futures Ordinance
	2. Kokusai is beneficially owned Yee is deemed to be interest for the purpose of the SFO.		
	3. Mr. Zhang hold 4,000,000 sh	are options grante	d on 9 April 2020.
Name(s) of company(ies) listed on GEM or the Main Board of the Stock Exchange within the same group as the Company:	N/A		
Financial year end date:	31 December		

Registered address:

Cricket Square,
Hutchins Drive,
P.O. Box 2681,
Grand Cayman KY1-1111, Cayman Islands

THE STOCK EXCHANGE OF HONG KONG LIMITED

(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

Head office and principal place of business:	Head office and principal place of business in Hong KongRoom 04, 9 Floor, Kimberley House,35-35A Kimberley Road,Tsim Sha Tsui,Kowloon,Hong KongPrincipal place of business in the PRC1-3/F, Building D, Shenzhen Junxuan,No.16 Yinkui Road,Kui Xin Community,Kui Chong Office,Dapeng New District,Shenzhen,the PRC
Web-site address (if applicable):	www.huakangbiomedical.com
Share registrar:	Principal share registrar and transfer office in Cayman Islands Conyers Trust Company (Cayman) Limited Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111, Cayman Islands Hong Kong branch share registrar and transfer office Tricor Investor Services Limited 17/F., Far East Finance Centre, 16 Harcourt Road, Hong Kong
Auditors:	Mazars CPA Limited 42/F., Central Plaza, 18 Harbour Road, Wanchai, Hong Kong

B. Business activities

(Please insert here a brief description of the business activities undertaken by the Company and its subsidiaries.)

A medical device group specialised in the research and development, manufacture and sale of a wide range of invitro diagnostic ("IVD") reagents and auxiliary reproductive supplies and equipment in the People's Republic of China ("PRC").

THE STOCK EXCHANGE OF HONG KONG LIMITED

(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

C. Ordinary shares	
Number of ordinary shares in issue:	469,472,000
Par value of ordinary shares in issue:	HK\$0.01 per Share
Board lot size (in number of shares):	8,000
Name of other stock exchange(s) on which ordinary shares are also listed:	N/A
D. Warrants	
Stock code:	N/A
Board lot size:	N/A
Expiry date:	N/A
Exercise price:	N/A
Conversion ratio: (Not applicable if the warrant is denominated in dollar value of conversion right)	N/A
No. of warrants outstanding:	N/A
No. of shares falling to be issued upon the exercise of outstanding warrants:	N/A

E. Other securities

Details of any other securities in issue.

(i.e. other than the ordinary shares described in C above and warrants described in D above but including options granted to executives and/or employees).

On 9 April 2020, the Company announced the granting of an aggregate of 26,008,000 share options, in which 16,000,000 Share Options were granted to the executive Directors of the Company, at an exercise price of HK\$0.125 per share of the Company to the eligible persons under the Share Option Scheme. The market price of the Company's shares at the date of grant was HK\$0.125 per share. All of the share options are exercisable from the date of acceptance by a grantee to 8 April 2030 (both days inclusive). Each of the grantees had paid HK\$1 to the Company on acceptance of the offer of share option. No share options have been lapsed, however, 4,000,000 share options have been exercised and 2,504,000 share options have been forfeited up to date of this letter.

(Please include details of stock code if listed on GEM or the Main Board or the name of any other stock exchange(s) on which such securities are listed).

If there are any debt securities in issue that are guaranteed, please indicate name of guarantor.

Ν/Α

THE STOCK EXCHANGE OF HONG KONG LIMITED (A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

Responsibility statement

The directors of the Company (the "Directors") as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet ("the Information") and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading or deceptive and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

Submitted by:

Chau Lai Ki (Name)

Title:

Company Secretary (Director, secretary or other duly authorised officer)

NOTE

Pursuant to rule 17.52 of the GEM Listing Rules, the Company must submit to the Exchange (in the electronic format specified by the Exchange from time to time) for publication on the Exchange's website a revised information sheet as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.